Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.40 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.40 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.40 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8846631 | 0.88 | TSHR (0.45) | CA1CA2CLCN2GABRPGABRD | |
| SCHEMBL11021926 | 0.87 | CA1 (0.44) | CA1CA2SELLSELPCSNK2A1 | |
| SCHEMBL21221620 | 0.85 | MCL1 (0.47) | CA1CA2SELLSELPCSNK2A1 | |
| SCHEMBL3256019 | 0.85 | TSHR (0.47) | CSNK2A1CLCN2CTSBGABRPGABRD | |
| SCHEMBL31668786 | 0.84 | SELL (0.48) | CA1CA2SELLSELPCSNK2A1 | |
| SCHEMBL542401 | 0.84 | SELL (0.48) | CA1CA2SELLSELPCSNK2A1 | |
| SCHEMBL39790 | 0.82 | SELL (0.57) | CA1CA2SELLSELPCSNK2A1 | |
| SCHEMBL5925607 | 0.81 | GABRP (0.45) | CLCN2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL294836 | 0.81 | CYP1A2 (0.50) | CA1CA2SELLSELPCLCN2 | |
| SCHEMBL18419577 | 0.81 | SELL (0.45) | CA1CA2SELLSELPCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-1984324-B1 | MANDELIC HYDRAZIDES | MERCK PATENT GMBH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2260028-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Radius Health, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| US-7776920-B2 | Mandelic hydrazides | MERCK PATENT GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090221712-A1 | MANDELIC HYDRAZIDES | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-03 | — | — | US | disclosed |
| WO-2009105214-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2009-08-27 | — | — | WO | disclosed |
| CN-101374800-A | Mandelic hydrazides | MERCK PATENT GMBH (DE) | 2009-02-25 | — | — | CN | disclosed |
| EP-1984324-A1 | MANDELIC HYDRAZIDES | Merck Patent GmbH (DE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007093264-A1 | MANDELIC HYDRAZIDES | MERCK PATENT GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-0791590-B1 | Benzothiophenes, and formulations and methods using same | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6432982-B1 | TREATING POST-MENOPAUSAL WOMEN HAVING OSTEOPOROSIS, CARDIOVASCULAR DISORDERS AND ESTROGEN-DEPENDENT CANCER; RESTENOSIS INHIBITION; ENDOMETRIOSIS | ELI LILLY AND COMPANY | 2002-08-13 | — | — | US | disclosed |
| WO-1997030985-A1 | BENZOTHIOPHENES, AND FORMULATIONS AND METHODS, USING SAME | ELI LILLY AND COMPANY (US) | 1997-08-28 | — | — | WO | disclosed |
| EP-0791590-A1 | Benzothiophenes, and formulations and methods using same | ELI LILLY AND COMPANY (US) | 1997-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221712-A1 | MANDELIC HYDRAZIDES | HK1, GLS, AGK | CA1 3004/4885CA2 883/4885SELL 4495/4885 |
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | CA1 3733/4885CA2 1838/4885SELL 4008/4885 |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | AR, SHBG, IGF1R | CA1 3946/4885CA2 2507/4885SELL 3733/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | CA1 3733/4885CA2 1838/4885SELL 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.